Standard Biotools Stock Performance
| LAB Stock | USD 1.30 0.03 2.26% |
On a scale of 0 to 100, Standard Biotools holds a performance score of 4. The entity has a beta of 3.09, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Standard Biotools will likely underperform. Please check Standard Biotools' semi deviation, jensen alpha, maximum drawdown, as well as the relationship between the coefficient of variation and sortino ratio , to make a quick decision on whether Standard Biotools' existing price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Standard Biotools are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Standard Biotools sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Disposition of 6364 shares by Hanjoon Kim of Standard Biotools at 1.05 subject to Rule 16b-3 | 05/20/2025 |
2 | Disposition of 1407 shares by Hanjoon Kim of Standard Biotools at 1.03 subject to Rule 16b-3 | 05/21/2025 |
3 | Disposition of 12536 shares by Sean Mackay of Standard Biotools at 1.002 subject to Rule 16b-3 | 05/22/2025 |
4 | Disposition of 5473 shares by Michael Egholm of Standard Biotools at 0.941 subject to Rule 16b-3 | 05/23/2025 |
5 | Standard BioTools to Host Inaugural Proteomics Roundtable Webcast Series | 05/30/2025 |
6 | Acquisition by Cox Troy of 72213 shares of Standard Biotools at 1.77 subject to Rule 16b-3 | 06/18/2025 |
7 | Acquisition by Witney Frank of 125660 shares of Standard Biotools at 1.05 subject to Rule 16b-3 | 06/20/2025 |
8 | Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to ... | 06/23/2025 |
9 | Illumina SomaLogic , | 06/26/2025 |
10 | Illumina to Acquire SomaLogic for 350 Million, Expanding into Proteomics and Precision Medicine | 07/03/2025 |
11 | KONET Officially Launches KONET LAB, a Platform Where Anyone Can Create Web3 Tokens | 07/07/2025 |
12 | Is Standard BioTools Inc. a good long term investment - Game-changing capital returns - Jammu Links News | 07/18/2025 |
13 | CORE LAB REPORTS SECOND QUARTER 2025 RESULTS | 07/23/2025 |
14 | Is it the right time to buy Standard BioTools Inc. stock - Post Market Planner That Work - jammulinksnews.com | 08/01/2025 |
| Begin Period Cash Flow | 52.5 M | |
| Total Cashflows From Investing Activities | 363.2 M |
Standard Biotools Relative Risk vs. Return Landscape
If you would invest 115.00 in Standard Biotools on May 5, 2025 and sell it today you would earn a total of 15.00 from holding Standard Biotools or generate 13.04% return on investment over 90 days. Standard Biotools is generating 0.3183% of daily returns assuming volatility of 5.0709% on return distribution over 90 days investment horizon. In other words, 45% of stocks are less volatile than Standard, and above 94% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Standard Biotools Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Standard Biotools' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Standard Biotools, and traders can use it to determine the average amount a Standard Biotools' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0628
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LAB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.07 actual daily | 45 55% of assets are more volatile |
Expected Return
| 0.32 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Standard Biotools is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Standard Biotools by adding it to a well-diversified portfolio.
Standard Biotools Fundamentals Growth
Standard Stock prices reflect investors' perceptions of the future prospects and financial health of Standard Biotools, and Standard Biotools fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Standard Stock performance.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.78) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 241.28 M | ||||
| Shares Outstanding | 361.24 M | ||||
| Price To Earning | (2.52) X | ||||
| Price To Book | 1.03 X | ||||
| Price To Sales | 2.83 X | ||||
| Revenue | 174.43 M | ||||
| Gross Profit | 79.81 M | ||||
| EBITDA | (118.14 M) | ||||
| Net Income | (138.88 M) | ||||
| Cash And Equivalents | 81.31 M | ||||
| Cash Per Share | 2.68 X | ||||
| Total Debt | 33 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 5.87 X | ||||
| Book Value Per Share | 1.23 X | ||||
| Cash Flow From Operations | (143.45 M) | ||||
| Earnings Per Share | (0.32) X | ||||
| Market Capitalization | 480.49 M | ||||
| Total Asset | 612.34 M | ||||
| Retained Earnings | (1.19 B) | ||||
| Working Capital | 309.99 M | ||||
About Standard Biotools Performance
By analyzing Standard Biotools' fundamental ratios, stakeholders can gain valuable insights into Standard Biotools' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Standard Biotools has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Standard Biotools has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 164.90 | 196.27 | |
| Return On Tangible Assets | (0.29) | (0.31) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.29) | (0.31) |
Things to note about Standard Biotools performance evaluation
Checking the ongoing alerts about Standard Biotools for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Standard Biotools help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Standard Biotools had very high historical volatility over the last 90 days | |
| Standard Biotools may become a speculative penny stock | |
| The company reported the last year's revenue of 174.43 M. Reported Net Loss for the year was (138.88 M) with profit before taxes, overhead, and interest of 79.81 M. | |
| Standard Biotools has about 81.31 M in cash with (143.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Standard Biotools has a poor financial position based on the latest SEC disclosures | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Is it the right time to buy Standard BioTools Inc. stock - Post Market Planner That Work - jammulinksnews.com |
- Analyzing Standard Biotools' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Standard Biotools' stock is overvalued or undervalued compared to its peers.
- Examining Standard Biotools' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Standard Biotools' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Standard Biotools' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Standard Biotools' stock. These opinions can provide insight into Standard Biotools' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Standard Stock analysis
When running Standard Biotools' price analysis, check to measure Standard Biotools' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Biotools is operating at the current time. Most of Standard Biotools' value examination focuses on studying past and present price action to predict the probability of Standard Biotools' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Biotools' price. Additionally, you may evaluate how the addition of Standard Biotools to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |